Advantages:

To evaluate visual and anatomical outcomes of macular edema (ME) secondary to central retinal vein occlusion (CRVO) after early onset treatment with intravitreal injections of bevacizumab (IVB).

Methods:

Ten consecutive eyes with ME secondary to nonischemic CRVO were included in this retrospective study. All patients had fundus fluorescein angiography (FFA) and optical coherence tomography at presentation. All patients were treated with an initial intravitreal injection of 1.25 mg bevacizumab. Retreatment criteria was based on OCT findings. Data was collected at baseline and first week, first month and third months of injection. Best corrected visual acuity (BCVA), central foveal thickness (CFT) on OCT and complications of injection were evaluated.

Effectiveness / Safety:

Mean age was 64.3 ±12.1 (36-79). Mean time between onset of symptoms and IVB was 35 ±15.8 days (10-60 days). Mean baseline BCVA (LogMAR) was 0.82 ±0.4 compared to 0.4 ±0.34 at first week,  0.36 ±0.33 at first month, 0.33 ±0.3 at third month of injection.